About Promedior
Promedior is a company based in Lexington (United States) founded in 2006 was acquired by Roche in November 2019.. Promedior has raised $49.76 million across 6 funding rounds from investors including Roche, Takeda Pharmaceuticals and Morgenthaler. The company has 9 employees as of December 31, 2022. Promedior operates in a competitive market with competitors including Reneo Pharmaceuticals, Alentis Therapeutics, Sionna, Blade Therapeutics and Avalyn Pharma, among others.
- Headquarter Lexington, United States
- Employees 9 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Promedior, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
62 people
Software Development Team
54 people
Human Resources and Administration
40 people
Finance and Accounting
37 people
Operations Team
36 people
Product Management Team
31 people
Sales and Marketing
22 people
Senior Team
19 people
Unlock access to complete
Funding Insights of Promedior
Promedior has successfully raised a total of $49.76M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $3 million completed in October 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series D — $3.0M
-
First Round
First Round
(01 Jul 2008)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2012 | Amount | Series D - Promedior | Valuation |
investors |
|
| Mar, 2012 | Amount | Series D - Promedior | Valuation | Morgenthaler , Healthcare Ventures |
|
| Oct, 2011 | Amount | Debt – Conventional - Promedior | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Promedior
Promedior has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, Takeda Pharmaceuticals and Morgenthaler. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity investment firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Promedior
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Promedior
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Promedior Comparisons
Competitors of Promedior
Promedior operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reneo Pharmaceuticals, Alentis Therapeutics, Sionna, Blade Therapeutics and Avalyn Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Small molecule therapies for orphan diseases are being developed.
|
|
| domain | founded_year | HQ Location |
Therapies for fibrosis, cirrhosis, and liver cancer are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cystic fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
Antifibrotic strategies are developed for congenital and acquired fibrotic diseases.
|
|
| domain | founded_year | HQ Location |
Therapies for treating Idiopathic Pulmonary Fibrosis are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Promedior
Frequently Asked Questions about Promedior
When was Promedior founded?
Promedior was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Where is Promedior located?
Promedior is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Is Promedior a funded company?
Promedior is a funded company, having raised a total of $49.76M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $6.5M, raised on Jul 01, 2008.
How many employees does Promedior have?
As of Dec 31, 2022, the latest employee count at Promedior is 9.
What does Promedior do?
Promedior is a clinical-stage biotechnology company that develops targeted therapeutics to treat diseases involving fibrosis. Promediors proprietary platform is based upon Pentraxin-2, an endogenous human protein that is a monocytemacrophage differentiation factor specifically active at the site of tissue damage and works as an agonist with the potential to both prevent and reverse fibrosis. The companys lead product candidate is a recombinant form of human Pentraxin-2 called PRM-151 in development for the treatment rare systemic fibrotic diseases, such as Idiopathic Pulmonary Fibrosis (IPF) (Phase 1) and myelofibrosis (Phase 2). Its lead ocular product candidate PRM-167 human pentraxin-2 protein developed specifically for intravitreal delivery in retinal fibrovascular diseases such as Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) and is in the preclinical stage.
Who are the top competitors of Promedior?
Promedior's top competitors include Arcturus Therapeutics, Reneo Pharmaceuticals and Sionna.
Who are Promedior's investors?
Promedior has 7 investors. Key investors include Roche, Takeda Pharmaceuticals, Morgenthaler, Healthcare Ventures, and Polaris Partners.